While millions obsess over LDL, top cardiologists reveal that a single "sticky" protein marker provides the most accurate ...

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...

Scientists have taken a decisive step toward ending one of transplant medicine’s most stubborn bottlenecks: the need to match donor organs to a recipient’s blood type. By chemically reengineering a ...